Generated by All in One SEO v4.9.7.2, this is an llms.txt file, used by LLMs to index the site.

# Destina Genomics

Simultaneous detection of nucleic acids and proteins

## Sitemaps

- [XML Sitemap](https://destinagenomics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery](https://destinagenomics.com/short-communication-mirna122-interrogation-via-pcr-free-method-to-track-liver-recovery/) - Citation: PLoS One 20(5): e0324858. DOI: 10.1371/journal.pone.0324858 Abstract There is currently a need to investigate new biomarkers of acute liver injury (ALI) that are highly specific to the liver and capable of detecting early-stage liver damage. In this regard, circulating microRNAs (miRNAs), particularly microRNA122 (miRNA122), have recently been proposed as promising new candidate biomarkers. However,
- [Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories](https://destinagenomics.com/dynamic-chemical-labelling-allows-the-measurement-of-the-paracetamol-toxicity-biomarker-microrna-122-in-hospital-clinical-laboratories/) - Citation: Br J Clin Pharmacol. 2025; 1–7 DOI: 10.1002/bcp.70364 Abstract MicroRNA-122 (miR-122) is a sensitive biomarker for paracetamol-induced liver injury. This study assessed the diagnostic performance of dynamic chemical labelling (DCL) combined with an immunoassay platform to quantify miR-122 in human serum, as a proof-of-concept for hospital use. This study used serum samples from 19 healthy individuals
- [DNA Analysis by Dynamic Chemistry](https://destinagenomics.com/dna-analysis-by-dynamic-chemistry/) - Citation: Angewandte Chemie International Edition, 2010, 49, 1809–1812. Abstract Finding flaws: An enzyme‐free method of DNA analysis raises the possibility of analyzing single‐nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. The methodology is suitable for the dual analysis of heterozygous samples.
- [Dynamic chemistry for enzyme-free allele discrimination in genotyping by MALDI-TOF mass spectrometry](https://destinagenomics.com/dynamic-chemistry-for-enzyme-free-allele-discrimination-in-genotyping-by-maldi-tof-mass-spectrometry/) - Abstract Single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) constitute important sources of genetic variation which provide insight into disease origins and differences in drug responses. The analysis of such genetic variation relies upon the generation of allele-specific products, typically by enzymatic extension or alternatively by the hybridization of DNA probes. MALDI-TOF mass spectrometry (MS) has been widely used as a read-out
- [Novel Biochip Platform for Nucleic Acid Analysis](https://destinagenomics.com/novel-biochip-platform-for-nucleic-acid-analysis/) - Citation Sensors, 2012, 12, 8100-8111. Abstract This manuscript describes the use of a novel biochip platform for the rapid analysis/identification of nucleic acids, including DNA and microRNAs, with very high specificity. This approach combines a unique dynamic chemistry approach for nucleic acid testing and analysis developed by DestiNA Genomics with the STMicroelectronics In-Check platform, which comprises two microfluidic optimized
- [Novel bead-based platform for direct detection of unlabelled nucleic acids through Single Nucleobase Labelling](https://destinagenomics.com/novel-bead-based-platform-for-direct-detection-of-unlabelled-nucleic-acids-through-single-nucleobase-labelling/) - Citation: Talanta, 2016, 161, 489-496 Abstract Over the last decade, circulating microRNAs have received attention as diagnostic and prognostic biomarkers. In particular, microRNA122 has been demonstrated to be an early and more sensitive indicator of drug-induced liver injury than the widely used biomarkers such as alanine aminotransferase and aspartate aminotransferase. Recently, microRNA122 has been used in vitro to assess the cellular toxicity of
- [Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury](https://destinagenomics.com/polymerase-free-measurement-of-microrna-122-with-single-base-specificity-using-single-molecule-arrays-detection-of-drug-induced-liver-injury/) - Citation: PLOS One, 2017, doi: journal.pone.0179669 Abstract We have developed a single probe method for detecting microRNA from human serum using single molecule arrays, with sequence specificity down to a single base, and without the use of amplification by polymerases. An abasic peptide nucleic acid (PNA) probe—containing a reactive amine instead of a nucleotide at a specific position
- [Single Molecule MicroRNA Technology Proves Useful for Liver Toxicity Detection](https://destinagenomics.com/single-molecule-microrna-technology-proves-useful-for-liver-toxicity-detection/) - Breakthrough Research Published in PLOS ONE Demonstrates Quantitative, PCR-Free Detection of MicroRNA LEXINGTON, Mass. and EDINBURGH, UK—July 5, 2017— Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, and DestiNA Genomics Ltd, a manufacturer of patented reagents for nucleic acid detection, today announced that PLOS ONE has
- [Novel molecular assay based on ‘Single Nucleotide Fingerprints’ (SNF) for the diagnosis and monitoring of Trypanosomatids.](https://destinagenomics.com/single-nucleotide-fingerprints/) - Novel molecular assay based on ‘Single Nucleotide Fingerprints’ (SNF) for the diagnosis and monitoring of Trypanosomatids. EDINBURGH, UK and GRANADA, Spain—July 21, 2017— Researchers at the Centre for Genomics and Oncological Research (GENYO) located in Granada, Spain, in collaboration with DestiNA have developed a novel assay for the diagnosis and monitoring of Trypanosomatids. The method
- [Identification of Trypanosomatids by detecting Single Nucleotide Fingerprints using DNA analysis by dynamic chemistry with MALDI-ToF](https://destinagenomics.com/identification-of-trypanosomatids-by-detecting-single-nucleotide-fingerprints-using-dna-analysis-by-dynamic-chemistry-with-maldi-tof/) - Citation: Talanta, 2018, 299-307 Protozoan parasites of the Trypanosomatidae family can cause devastating diseases in humans and animals, such as Human African Trypanosomiasis or Sleeping Sickness, Chagas disease and Leishmaniasis. Currently, there are molecular assays for detecting parasitic infections and their post-treatment monitoring based on nucleic acid amplification, but there are still certain limitations which limit the
- [A PCR-free technology to detect and quantify microRNAs directly from human plasma](https://destinagenomics.com/news-publications-analyst-2018-143-5676-5682/) - Citation: Analyst, 2018, 143, 5676-5682 Abstract A novel sensitive, specific and rapid method for the detection and quantification of microRNAs without requiring extraction from their biological sources is now available using a novel chemical based, PCR-free technology for nucleic acid testing. In this study, we both demonstrate how this method can be used to profile miR-451a,
- [A colorimetric strategy based on dynamic chemistry for direct detection of Trypanosomatid species](https://destinagenomics.com/news-publications-a-colorimetric-strategy-based-on-dynamic-chemistry-for-direct-detection-of-trypanosomatid-species/) - Citation: Scientific Reports, 2019, 9, Article number: 3696 Abstract Leishmaniasis and Chagas disease are endemic in many countries, and re-emerging in the developed countries. A rapid and accurate diagnosis is important for early treatment for reducing the duration of infection as well as for preventing further potential health complications. In this work, we have developed a novel colorimetric molecular assay
- [Time-Gated Luminescence Acquisition for Biochemical Sensing: miRNA Detection](https://destinagenomics.com/time-gated-luminescence-acquisition-for-biochemical-sensing-mirna-detection/) - Citation: In: Pedras B. (eds) Fluorescence in Industry. Springer Series on Fluorescence (Methods and Applications), vol 18. Springer, Chamger Ser Fluoresc, DOI 10.1007/4243_2018_4 Abstracts Luminescence emission is a multidimensional phenomenon comprising a time-domain layer defined by its excited-state kinetics and corresponding lifetime, which is specific to each luminophore and depends on environmental conditions. This feature
- [New Platform for the Direct Profiling of microRNAs in Biofluids](https://destinagenomics.com/new-platform-for-the-direct-profiling-of-micrornas-in-biofluids/) - Citation: Anal. Chem., 2019, 91 (9), 5874–5880 Abstract Circulating microRNAs have been identified as potential biomarkers for early detection, prognosis, and prediction of several diseases. Their use in clinical diagnostics has been limited by the lack of suitable detection techniques. Most of the current technologies suffer from requiring complex protocols, not yet able to deliver robust and cost-effective
- [PCR-free and chemistry-based technology for miR-21 rapid detection directly from tumour cells](https://destinagenomics.com/news-publications-pcr-free-and-chemistry-based-technology-for-mir-21-rapid-detection-directly-from-tumour-cells/) - Citation: Talanta, 2019, 51-56 Abstract miRNAs are well known for being implicated in a myriad of biological situations, including those related to serious diseases. Amongst miRNAs, miRNA-21 has the spotlight as it is reported to be up-regulated in multiple severe pathological conditions, being its quantification a key point in medicine. To date, most of the techniques for miRNA quantification
- [miR-122 direct detection in human serum by time-gated fluorescence imaging](https://destinagenomics.com/news-publications-mir-122-direct-detection-in-human-serum-by-time-gated-fluorescence-imaging/) - Citation: Chem. Commun., 2019, 55, 14958-14961 Abstract A simple method for direct detection of microRNAs (miRs) in human serum without the use of polymerase amplification is presented, achieving low miR-122 concentrations and importantly, discerning effectively single-base sequence mutations. The method is based on the capture of target miRs with synthetic peptide nucleic acid oligomers, dynamic chemical labelling,
- [Smartphone-Based Diagnosis of Parasitic Infections With Colorimetric Assays in Centrifuge Tubes](https://destinagenomics.com/news-publications-smartphone-based-diagnosis-of-parasitic-infections-with-colorimetric-assays-in-centrifuge-tubes/) - Citation: IEEE Access, 2019, 7, 185677 – 185686 DOI:10.1109/ACCESS.2019.2961230 Abstract A smartphone-based platform for the diagnosis of parasitic infections has been developed, tested and validated. The system is capable of making automatic and accurate analysis of millimetric colorimetric arrays in centrifuge collection tubes, which are well established tools used in clinical analysis. To that end, an Android-based
- [Direct Detection of miR-122 in Hepatotoxicity Using Dynamic Chemical Labeling Overcomes Stability and isomiR Challenges](https://destinagenomics.com/news-publications-direct-detection-of-mir-122-in-hepatotoxicity-using-dynamic-chemical-labeling-overcomes-stability-and-isomir-challenges/) - Citation: Analytical Chemistry, 2020, doi: 10.1021/acs.analchem.9b05449 Abstract Circulating microRNAs are biomarkers reported to be stable and translational across species. MicroRNA-122 (miR-122) is a hepatocyte-specific microRNA biomarker for drug-induced liver injury (DILI). We developed a single molecule, dynamic chemical labeling (DCL) assay to directly detect miR-122 in blood. The DCL assay specifically measured miR-122 directly from 10
- [DESTINA & SMCxPro featuring at Biomarker Series UK Conference in Manchester](https://destinagenomics.com/destina-smcxpro-featuring-at-biomarker-series-uk-conference-in-manchester/) - On 20th February 2020 at 9:30am GMT, Hugh Ilyine will present, during the New Biomarker Technologies & Data Session, the integration of DESTINA Chemistry within Merck SMCxPro platform for quantifying miRNA molecules directly from body fluids. The title of his talk is Novel Single Molecule Counting (SMC) Of MicroRNA By A PCR Free Method. See
- [Redesigned DESTINA website goes live](https://destinagenomics.com/redesigned-destina-website-goes-live/) - DESTINA Genomics has a new redesigned and upgraded website at www.destinagenomics.com Now live, the modernised web design makes access easy to our product and services for PCR free, highly accurate and quantifiable detection of RNA Biomarkers. DESTINA’s unique patented chemistry and how it works is now explained using a 3D Video, with a dynamic new
- [DESTINA Genomica S.L. joins Science Exchange](https://destinagenomics.com/destina-genomica-s-l-joins-science-exchange/) - DESTINA Genomica SL has joined @Science Exchange, the global platform for outsourced R&D reagents and services. For quotations on the supply of RNA profiling services and custom PNAs synthesis for your research, just contact us via our website. Orders on acceptance can then be made securely through https://www.scienceexchange.com/labs/destina-genomica-sl
- [Announcement on the Death of our CEO Hugh Ilyine](https://destinagenomics.com/announcement-on-the-death-of-hugh-ilyine/) - Edinburgh 23rd September 2020 It is with great sadness that DESTINA Genomics and DESTINA Genomica announce the death of our friend, colleague and CEO Hugh Ilyine. Hugh was found at his desk having only recently been on a call where he had been his usual ebullient and energetic self. Hugh was a founding director and
- [Juanjo’s Eulogy for Hugh - My mentor, friend and companion](https://destinagenomics.com/juanjos-eulogy-for-hugh-my-mentor-friend-and-companion/) - Granada 12th October 2020 I was a Spanish academic researcher living in the UK who always wanted to commercialise some of my research through creating a company. I have a happy family background but none of them went onto higher education nor were they high net worth individuals, a ground zero individual as Hugh used
- [Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the Luminex MAGPIX system](https://destinagenomics.com/amplification-free-profiling-of-microrna-122-biomarker-in-dili-patient-serums-using-the-luminex-magpix-system/) - Citation: Talanta, 2020, doi: 10.1016/j.talanta.2020.121265 Abstract Dynamic chemical labelling is a single-base specific method to enable detection and quantification of micro-Ribonucleic Acids in biological fluids without extraction and pre-amplification. In this study, dynamic chemical labelling was combined with the Luminex MAGPIX system to profile levels of microRNA-122 biomarker in serum from patients with Drug-Induced Liver Injury.
- [Announcement on the Death of our CEO Hugh Ilyine](https://destinagenomics.com/announcement-on-the-death-of-our-ceo-hugh-ilyine/) - Edinburgh 23rd September 2020 It is with great sadness that DESTINA Genomics and DESTINA Genomica announce the death of our friend, colleague and CEO Hugh Ilyine. Hugh was found at his desk having only recently been on a call where he had been his usual ebullient and energetic self. Hugh was a founding director and
- [The European Comission award DESTINA the diar](https://destinagenomics.com/the-european-comission-award-destina-the-diar/) - [ultimate_heading main_heading=”Technology” heading_tag=”h1″ main_heading_margin=”margin-bottom:20px;”] The three major DESTINA technologies are unique and distinguishable from ALL existing enzymatic methods of nucleic acid analysis. [/ultimate_heading] DGL-TechTM DGL-TechTM for nucleic acid analysis combines patented SMART-Bases with unique peptide nucleic acid (PNA) capture More ChemiRNATM Tech ChemiRNATM Tech are small non-coding RNAs of 19–24 nucleotides in length with a big role
- [DESTINA featuring at Virtual Symposium On Ultrasensitive Immunoassays: The Power of Single Molecule Counting (SMC™) Technology organised by MilliporeSigma](https://destinagenomics.com/destina-featuring-at-virtual-symposium-on-ultrasensitive-immunoassays-the-power-of-single-molecule-counting-smc-technology-organised-by-milliporesigma-labroots/) - On Wednesday 31 March 2021, DESTINA’s Juan Jose Diaz-Mochon will present the First Single Molecule Counting (SMC™) Application with miRNAs by a PCR Free Method. You can register here to watch the presentation https://lnkd.in/eiMknq9The high specificity of DESTINA technologies has been implemented within the ultrasensitive SMC™ to yield the platform’s first molecular assays. During his presentation, Juan will
- [DESTINA Genomics and Mecwins join forces to develop more reliable diagnostic tests](https://destinagenomics.com/destina-genomics-and-mecwins-join-forces-to-develop-more-reliable-diagnostic-tests/) - DESTINA Genomics and Mecwins join forces to develop more reliable diagnostic tests Both biotechnology firms have signed a cross-licensing agreement to share technology to develop RNA quantification tests directly from biological samples. Initial tests will focus both on RNA biomarkers for drug-induced hepatotoxicity, nephrotoxicity and cardiotoxicity, and on therapeutic RNAs. Thanks to the combination
- [OPEN A NEW WINDOW ON THE WORLD OF CIRCULATING MICRORNA BIOMARKERS BY MERGING CHEMIRNATM TECH WITH AVAC ANALYZER](https://destinagenomics.com/open-a-new-window-on-the-world-of-circulating-microrna-biomarkers-by-merging-chemirnatm-tech-with-avac-analyzer/) - We are excited to announce a new project that changes the way we analyze miRNA-122. This small non-coding RNA is known as a biomarker for liver injury. With the support of the 2022 ICEX-Invest in Spain's funding program, we are implementing the unique PCR-Free testing of miRNA-122 using DESTINA's ChemiRNATM Tech reagents merged with AVAC
- [Diagnosing Alzheimer's Disease - Project granted with more than €1.3 million in aid under the Colaboración Público Privada Program](https://destinagenomics.com/diagnosing-alzheimers-disease-project-granted-with-more-than-e1-3-million-in-aid-under-the-colaboracion-publico-privada-program/) - Destina Genomica SL is part of a consortium formed by the Foundation for Biomedical Research of the Ramón y Cajal University Hospital (Madrid, Spain), the Advanced Photonic and Biofunctional Materials Group of the UAM (Autonomous University of Madrid, Spain) and led by the Spanish company Mecwins SA (Madrid) that has just received a grant of
- [Industrial PhD position - ColoMark Project - CLOSED](https://destinagenomics.com/industrial-phd-position-colomark-project/) - An industry-focused research position is now available at DESTINA Genomica S.L. If you are interested to contribute with your research to discover novel biomarkers for colorectal cancer and develop novel liquid biopsy technologies, go and check out our outstanding DC6 project position to undertake your industrial PhD in! The doctoral candidate (DC) position is part
- [Job Opening - Quick Hire - Assay Development Scientist](https://destinagenomics.com/job-opening-quick-hire-assay-development-scientist/) - Job Opening Assay Development Scientist Company: DESTINA Genomica SL Location: Granada (Spain) Start Date: 1st November 2023 About Us: DESTINA Genomica SL is a biotech company at the interface of molecular and protein detection, leading the field with our dedicated and innovative team. We invite you to join us as an Assay Development Scientist where
- [MAGPIX and FLEXMAP 3D Luminex platforms for direct detection of miR-122-5p through dynamic chemical labelling](https://destinagenomics.com/magpix-and-flexmap-3d-luminex-platforms-for-direct-detection-of-mir-122-5p-through-dynamic-chemical-labelling/) - Citation: Analyst, 2023, Advance Article DOI: 10.1039/D3AN01250F Abstract MicroRNAs (miRs) have emerged as promising biomarkers for diagnosing and predicting the prognosis of liver injury. This study aimed to compare the performance of two Luminex platforms, MAGPIX and FLEXMAP 3D, utilizing the innovative Dynamic Chemical Labelling (DCL) technology for direct detection and analysis of miR-122-5p in
- [Evaluation of diagnostic and prognostic candidate biomarkers in drug-induced liver injury vs. other forms of acute liver damage](https://destinagenomics.com/evaluation-of-diagnostic-and-prognostic-candidate-biomarkers-in-drug-induced-liver-injury-vs-other-forms-of-acute-liver-damage/) - Citation: Br J Clin Pharmacol. 2023; 89:2497–2507 DOI:10.1111/bcp.15724 Abstract Aims Detection and characterization of idiosyncratic drug-induced liver injury (DILI) currently rely on standard liver tests, which are suboptimal in terms of specificity, sensitivity and prognosis. Therefore, DILI diagnosis can be delayed, with important consequences for the patient. In this study, we aimed to evaluate the

## Pages

- [Front Page](https://destinagenomics.com/) - Enable routine miRNA use in drug development with Destina’s PCR-free technology. Single-well multi-omic assays ensuring data integrity for FDA/EMA submissions.
- [Scientific publications](https://destinagenomics.com/scientific-publications/) - Literature | Destina Genomics Unlocking the Power of miRNA Biomarkers The Power Behind PCR-Free Diagnostics. PCR misses isomiR variants that alter your data integrity Extraction and amplification = hidden sources of variability Multi-Omic = Single well RNA + Protein detection Destina Chemistry = Direct quantification, zero amplification bias What Interests You? Select your primary interest...
- [Contact](https://destinagenomics.com/contact/) - Contact Us We are here to help. Send us a message or find our offices below. Send us a Message Your Name (required) Your Email (required) Your Phone (required) Subject Your Message (required) Human Verification: By submitting this form, you agree to our privacy policy. Human verification is required to prevent automated spam. Our Offices
- [Documentation](https://destinagenomics.com/documentation/) - Documentation Hub | Destina Genomics Home › Documentation Product Support Documentation Instructions for Use, Safety Data Sheets, Technical Datasheets, and Certificates of Analysis for all Destina Genomics products. LiverAce™ SinglePlex LiverAce™ COMBO More products coming LiverAce™ SinglePlex miRNA-122 Detection PCR-Free Luminex Ready Cross-Species RUO For Research Use Only. Not for diagnostic or clinical use. Instructions
- [RUO LiverAce COMBO Kit](https://destinagenomics.com/liverace-combo-kit/) - LiverAce™ COMBO Kit | Destina Genomica The Challenge of Liver toxicity in drug development: Early and Accurate Detection of Liver Toxicity across development stages. $3 Billion Annual cost to Pharma due to late-stage toxicity failures. #1 Cause DILI is the leading cause of acute liver failure worldwide. 750+ Drugs Medications currently linked to liver injury
- [RUO LiverAce SinglePlex Kit](https://destinagenomics.com/liverace-singleplex-kit/) - LiverAce™ Singleplex Kit | Destina Genomica The Challenge of Liver toxicity in drug development: Early and Accurate Detection of Liver Toxicity across development stages. $3 Billion Annual cost to Pharma due to late-stage toxicity failures. #1 Cause DILI is the leading cause of acute liver failure worldwide. 750+ Drugs Medications currently linked to liver injury
- [Team](https://destinagenomics.com/team/) - Destina Genomics Team ✦ Global Expertise Our Team A unified team of veterans and innovators driving the future of RNA detection through integrity and scientific excellence. Contact Management In Memoriam In Memoriam and honoring the Legacy of Humanism of Hugh
- [Peptide Nucleic Acids (PNAs)](https://destinagenomics.com/peptide-nucleic-acids-pnas/) - Custom PNA Synthesis | Destina Genomica 20+ Years Pioneering PNA Synthesis Custom PNA Synthesis: From Simple to Highly Complex Designs Stop compromising your biology due to synthesis limitations. While others reject complex designs, we deliver the exact molecule your research requires. Request a Quote Global Partnerships & Scientific Validation "Eventually we settled on Destina as
- [PR and News](https://destinagenomics.com/pr-and-news/) - News & Updates | Destina Genomics Home Products News News & Updates Corporate announcements, scientific milestones and latest developments. New Release Commercial Launch: Custom PNA Synthesis for Complex Designs PRODUCT LAUNCH • JANUARY 13, 2026 Redefining the boundaries of peptide nucleic acid synthesis: unrestricted full-spectrum customization tailored to your exact molecular requirements. Read full story
- [About Destina Chemistry](https://destinagenomics.com/about-destina-chemistry/) - Destina Chemistry | Destina Genomica The Power Behind PCR-Free Diagnostics Our platform-agnostic chemistry transforms standard immunoassay platforms into high-value workstations. By enabling direct, extraction-free detection of miRNAs, isomiRs, and proteins on any reader, Destina Chemistry provides the bridge between proteomics and the future of RNA therapeutics. Key Values Click on each badge to explore our
- [License Opportunity](https://destinagenomics.com/license-opportunity/) - License Opportunities | Destina Genomics Partner with Destina Genomics License the revolutionary Destina Chemistry and offer PCR-Free nucleic acid biomarker assays on immunoassay platforms. Schedule a Partnership Call The Service Lab Bottleneck Offering nucleic acid diagnostics, especially miRNA assays, is complex and expensive. Separate protein and nucleic acid workflows require different equipment, labs, and SOPs,
- [About us](https://destinagenomics.com/about-us/) - About Us | Destina Genomics The Company Destina Genomica S.L. is a specialized biotechnology company headquartered in Granada, Spain, dedicated to redefining the boundaries of molecular diagnostics and drug development through advanced chemical innovation. Our mission is to transform nucleic acid testing by commercializing our patented, platform-agnostic chemistry. We provide researchers and clinicians with absolute
- [Cookies Policy](https://destinagenomics.com/cookies-policy/) - Cookies Policy 1. Use of Cookies On the website www.destinagenomics.com, we use both our own and third-party cookies to provide you with a better browsing experience, enable content sharing on social networks, and obtain user statistics. You can prevent the installation of cookies by configuring your browser settings, thus preventing cookies from being stored on
- [Legal Notice](https://destinagenomics.com/legal-notice/) - Legal Notice and Terms of Use In this section, the USER can find all the information regarding the legal terms and conditions that define the relationship between users and us, as the entity responsible for this website.As a user, it is important that you read these terms carefully before continuing your navigation.DESTINA Genomica S.L., as
- [Privacy Policy](https://destinagenomics.com/privacy-policy/) - PRIVACY POLICY Controller – Who is responsible for the processing of your data? Identity: DESTINA Genomica S.L.Registesterd address: Avenida de la Innovación 1, 18016 Granada, Spain.Tax ID (CIF): B18998765Phone: +34 958 84 64 63Email: info@destinagenomics.comContact person: Juan Enrique Cruz RomeraDomain name: www.destinagenomics.com Purposes – For what purposes do we process your data? In compliance with the provisions of EU

## Portfolio

- [Pharmaceutical Development](https://destinagenomics.com/project/pharmaceutical-development/) - Morbi at laoreet mauris.
- [Genotyping Application](https://destinagenomics.com/project/genotyping-application/) - Lorem ipsum dolor sit amet.
- [Chemical Technology](https://destinagenomics.com/project/chemical-technology/) - Nulla a velit quis ex ornare rhoncus.
- [Genomic Science](https://destinagenomics.com/project/genomic-science/) - Ut elit luctus nec ullamcorper.
- [Lab Advance](https://destinagenomics.com/project/lab-advance/) - Lorem ipsum dolor sit amet.
- [Magazine](https://destinagenomics.com/project/magazine/) - Morbi at laoreet mauris.
- [Brand Design](https://destinagenomics.com/project/brand-design/) - Donec imperdiet risus justo.
- [Eco Package  Design](https://destinagenomics.com/project/eco-package-design/) - Lorem ipsum nulla glavrida.
- [S. V. N. Branding](https://destinagenomics.com/project/s-v-n-branding/) - Dolor uctus nec ullamcorper mattis.
- [Creative Logo](https://destinagenomics.com/project/creative-logo/) - Ut elit tellus pulvinar dapibus.

## Testimonials

- [Tiffany Richards](https://destinagenomics.com/dt_testimonials/tiffany-richards/) - "Sed in odio et enim venenatis luctus. In egestas orci quis magna iaculis eleifend. Proin a lobortis ante, nec eleifend urna. Pellentesque a enim elementum, tempor nulla id, ultrices augue. Maecenas sit amet tincidunt elit – habitant morbi tristique senectus!"
- [Diana Adams](https://destinagenomics.com/dt_testimonials/diama-adams/) - "Praesent sed fermentum augue. Sed in odio et enim venenatis luctus. In egestas orci quis magna iaculis eleifend. Proin a lobortis ante, nec eleifend urna. Pellentesque a enim elementum, tempor nulla id, ultrices augue. Maecenas sit amet tincidunt elit!"
- [James Remmington](https://destinagenomics.com/dt_testimonials/james-remmington/) - "Lorem pulvinar dapibus - malesuada erat fermentum velit quis ex ornare rhoncus. Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris. Thanx!"

## Categories

- [Uncategorized](https://destinagenomics.com/category/uncategorized/)
- [EVENTS](https://destinagenomics.com/category/events/)
- [PRESS RELEASES](https://destinagenomics.com/category/press-releases/)
- [PUBLICATIONS](https://destinagenomics.com/category/publications/)
- [Book Chapters](https://destinagenomics.com/category/book-chapters/)
- [Announcements](https://destinagenomics.com/category/announcements/)
- [Blog](https://destinagenomics.com/category/blog/)
- [Job offers](https://destinagenomics.com/category/job-offers/)

## Tags

- [ChemiRNA](https://destinagenomics.com/tag/chemirna/)
- [microRNA](https://destinagenomics.com/tag/microrna/)
- [MALDI-ToF](https://destinagenomics.com/tag/maldi-tof/)
- [DNA genotyping](https://destinagenomics.com/tag/dna-genotyping/)
- [Cystic Fibrosis](https://destinagenomics.com/tag/cystic-fibrosis/)
- [Dynamic Chemistry Labelling](https://destinagenomics.com/tag/dynamic-chemistry-labelling/)
- [DCL](https://destinagenomics.com/tag/dcl/)
- [DNA](https://destinagenomics.com/tag/dna/)
- [spin-tube](https://destinagenomics.com/tag/spin-tube/)
- [App](https://destinagenomics.com/tag/app/)
- [Direct Detection](https://destinagenomics.com/tag/direct-detection/)
- [Single Nucleotide Fingerprint](https://destinagenomics.com/tag/single-nucleotide-fingerprint/)
- [SNF](https://destinagenomics.com/tag/snf/)
- [Simoa](https://destinagenomics.com/tag/simoa/)
- [miR-122](https://destinagenomics.com/tag/mir-122/)
- [DILI](https://destinagenomics.com/tag/dili/)
- [miRNA-122](https://destinagenomics.com/tag/mirna-122/)
- [miR-21](https://destinagenomics.com/tag/mir-21/)
- [miRNA-21](https://destinagenomics.com/tag/mirna-21/)
- [lung cancer](https://destinagenomics.com/tag/lung-cancer/)
- [miR-451](https://destinagenomics.com/tag/mir-451/)
- [miRNA-451](https://destinagenomics.com/tag/mirna-451/)
- [Infectious Diseases](https://destinagenomics.com/tag/infectious-diseases/)
- [Trypanosomiasis](https://destinagenomics.com/tag/trypanosomiasis/)
- [Leishmaniasis](https://destinagenomics.com/tag/leishmaniasis/)
- [Luminex](https://destinagenomics.com/tag/luminex/)
- [Lab-on-Chip](https://destinagenomics.com/tag/lab-on-chip/)
- [Fluorescence](https://destinagenomics.com/tag/fluorescence/)
- [STM](https://destinagenomics.com/tag/stm/)
- [FLIM](https://destinagenomics.com/tag/flim/)
- [Life time fluorophore](https://destinagenomics.com/tag/life-time-fluorophore/)
- [SMCxPro](https://destinagenomics.com/tag/smcxpro/)
- [Conference](https://destinagenomics.com/tag/conference/)

## Portfolio Categories

- [Product Design](https://destinagenomics.com/project-category/product-design/)
- [Lab & Invest](https://destinagenomics.com/project-category/lab-invest/)